Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

VCEL Relative to the S&P 500

VCEL Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Vericel Corp. (NASD:VCEL) seasonal charts above shows that a Buy Date of October 16 and a Sell Date of January 10 has resulted in a geometric average return of 9.9% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 26.55% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various?therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

To download VCEL seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: VCEL